[Federal Register Volume 79, Number 19 (Wednesday, January 29, 2014)]
[Notices]
[Page 4757]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2014-01781]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Registration; 
Irix Manufacturing, Inc.

    By Notice dated August 5, 2013, and published in the Federal 
Register on August 14, 2013, 78 FR 49546, IRIX Manufacturing, Inc., 309 
Delaware Street, Greenville, South Carolina 29605, made application to 
the Drug Enforcement Administration (DEA) to be registered as a bulk 
manufacturer of Noroxymorphone (9668), a basic class of controlled 
substance listed in schedule II.
    The company plans to manufacture the listed controlled substance as 
API for clinical trials.
    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C. 823(a), and determined that the registration 
of IRIX Manufacturing, Inc., to manufacture the listed basic class of 
controlled substance is consistent with the public interest at this 
time. DEA has investigated IRIX Manufacturing, Inc., to ensure that the 
company's registration is consistent with the public interest. The 
investigation has included inspection and testing of the company's 
physical security systems, verification of the company's compliance 
with state and local laws, and a review of the company's background and 
history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 
21 CFR 1301.33, the above named company is granted registration as a 
bulk manufacturer of the basic class of controlled substance listed.

    Dated: January 15, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2014-01781 Filed 1-28-14; 8:45 am]
BILLING CODE 4410-09-P